NCT06737523View on ClinicalTrials.gov

Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid LeukemiaRelapseRefractory AML
Interventions
DRUG

CVA

Chiglitazar Sodium in combination with Venetoclax and Azacitidine

Trial Locations (1)

361000

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER